)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Clinical Laserthermia Systems
Clinical Laserthermia Systems (CLS) investor relations material
Clinical Laserthermia Systems Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary17 Jul, 2026
Executive summary
Sales of Prism products rebounded in Q2 2026 after strategic alignment with the neurosurgery partner, resulting in the largest purchase order in company history (SEK 23 million).
ClearPoint Prism System installations and procedures grew in the U.S., reflecting clinical and commercial momentum.
Extended research collaboration with the U.S. National Cancer Institute through 2029 to evaluate Tranberg Thermal Therapy System.
Strategic partnership agreement runs through 2030, supporting long-term growth in minimally invasive neurosurgery.
Financial highlights
Q2 2026 net sales: SEK 7.65 million, up 485% sequentially from Q1 2026, but below Q2 2025 (SEK 9.36 million).
Operating loss for Q2 2026: SEK -13.6 million (Q2 2025: SEK -2.9 million); H1 2026: SEK -23.2 million (H1 2025: SEK -10.8 million).
Net loss for Q2 2026: SEK -12.1 million (Q2 2025: SEK -6.3 million); H1 2026: SEK -19.5 million (H1 2025: SEK -21.6 million).
Gross margin stable at 62% in Q2 and YTD.
Cash and cash equivalents at end of Q2 2026: SEK 3.87 million (Q2 2025: SEK 16.2 million).
Outlook and guidance
Expects strong double-digit revenue growth for full-year 2026 versus 2025, with performance weighted to H2.
Revenue growth dependent on system placements and LITT procedure ramp-up; variability expected between quarters.
Additional capital required to reach positive cash flow by Q1 2028; financing preparations underway.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Clinical Laserthermia Systems
- Q1 2026 revenue fell 72%, but SEK 23 million in new orders set up strong growth for the year.CLS
Q1 2026 - Gross margin exceeded targets and Prism neurosurgery sales grew, despite lower total net sales.CLSQ4 2025
- FDA clearance and financing boost growth prospects as neurosurgery focus drives improved results.CLSQ3 2025
- Record Q2 sales and improved margins drive narrowed losses and strong growth outlook.CLSQ2 2025
- CLS accelerates neurosurgery growth, narrows losses, and targets profitability by 2026.CLSQ3 2024
- Revenue quadrupled and losses narrowed as neurosurgery focus and US expansion accelerated.CLSQ2 2024
- Revenue up 43% and operating loss halved as CLS accelerates neurosurgery commercialization.CLSQ1 2025
- CLS doubled sales, improved margins, and refocused on neurosurgery for high-margin growth.CLSQ4 2024
Next Clinical Laserthermia Systems earnings date
Q3 202613 Nov, 2026
Clinical Laserthermia Systems
Next Clinical Laserthermia Systems earnings date
Q3 202613 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Clinical Laserthermia Systems AB is a Swedish medical technology company focused on developing minimally invasive laser-based treatment systems for cancer and neurosurgery. The company’s flagship product is the TRANBERG Thermal Therapy System, which is designed for precision laser ablation of solid tumors. This system enables high-precision, image-guided treatments for conditions such as prostate cancer and brain lesions. CLS is also advancing imILT (immunostimulating interstitial laser thermotherapy), which combines laser ablation with immune system stimulation to treat various types of tumors, including those in the liver, lungs, and pancreas. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.